Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Constrained peptides' time to shine?

Nature Reviews Drug Discovery volume 17, pages 531–533 (2018)Cite this article

Subjects

Constrained peptides have long tantalized drug developers with their potential ability to combine the best attributes of antibodies and small molecules. Finally, a handful of constrained peptides are in late-stage clinical trials.

Peptides occupy a kind of Goldilocks space between small chemicals and large biologics, an intriguing area that theoretically combines the best characteristics of each traditional modality into 'just right' therapeutics. Whereas linear peptides tend to twist and flop in ways that make them too flaccid to make good drugs, drug developers have been working away on de novo cyclic peptides to harness increased stability and improved physicochemical characteristics for therapeutic effect. After decades of experimentation with novel constrained peptide formats, a few are at last entering the drug development end game.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Figure 1: Selected constrained peptide formats.
Authors
  1. Chris Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Morrison, C. Constrained peptides' time to shine?. Nat Rev Drug Discov 17, 531–533 (2018). https://doi.org/10.1038/nrd.2018.125

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2018.125

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing